CASI Pharmaceuticals, Inc. Stockholders Equity

Quick Answer

CASI Pharmaceuticals, Inc. reported Stockholders Equity of $1.85 million for the year ending 2024.

  • CASI Pharmaceuticals, Inc. showed a decrease of -92.3% in Stockholders Equity from 2023 to 2024.
  • This data is from CASI Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
  • XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2019 to 2024), CASI Pharmaceuticals, Inc.'s Stockholders Equity has declined by 97.5%.
  • Historical annual values: Fiscal year 2024: $1.85 million | Fiscal year 2023: $24.17 million | Fiscal year 2022: $44.57 million | Fiscal year 2021: $84.50 million | Fiscal year 2020: $81.54 million | Fiscal year 2019: $73.00 million.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: